All Stories

  1. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients
  2. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  3. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
  4. Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies
  5. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study
  6. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
  7. Current pharmacotherapeutic options for primary dyslipidemia in adults
  8. Safety and tolerability of available urate-lowering drugs: a critical review
  9. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction
  10. Emerging drugs for the treatment of hypercholesterolemia
  11. Nutraceutical Approach to Peripheral Neuropathies: Evidence from Clinical Trials
  12. Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases
  13. Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence
  14. Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials
  15. Immune modulation by curcumin: The role of interleukin-10
  16. Effects of Carotenoids on Health: Are All the Same? Results from Clinical Trials
  17. Emerging biologic therapies for hypercholesterolaemia
  18. Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients
  19. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
  20. Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects
  21. Profile of evolocumab and its potential in the treatment of hyperlipidemia
  22. Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations?
  23. Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments
  24. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
  25. THE TOTAL CARDIOVASCULAR RISK
  26. Uricaemia and ejection fraction in elderly heart failure outpatients
  27. Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users
  28. Berberine and Monacolin Effects on the Cardiovascular Risk Profile of Women with Oestroprogestin-Induced Hypercholesterolemia
  29. COST EFFECTIVENESS OF ZOFENOPRIL IN THE TREATMENT OF PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AFTER ACUTE MYOCARDIAL INFARCTION: A POST-HOC ANALYSIS OF THE SMILE-4 STUDY
  30. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence
  31. Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach
  32. Diet, dietary supplements and age-related macular degeneration (AMD)
  33. Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice
  34. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis
  35. RETRACTED: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation
  36. Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study
  37. Population Health Needs Assessment and Healthcare Services Use in a 3 Years Follow-Up on Administrative and Clinical Data: Results from the Brisighella Heart Study
  38. Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study
  39. Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease
  40. RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients
  41. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy
  42. Increased Serum Uric Acid as a Risk Factor for Cardiovascular Diseases
  43. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects
  44. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies
  45. Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4
  46. How to avoid the depression of the adherence to antihypertensive treatment?
  47. Effect of Zofenopril and Ramipril on Cardiovascular Mortality in Patients With Chronic Heart Failure
  48. RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients
  49. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction
  50. Combined Nutraceutical Approach to Postmenopausal Syndrome and Vascular Remodeling Biomarkers
  51. A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study
  52. Evidence of Clinically Relevant Efficacy for Dietary Supplements and Nutraceuticals
  53. Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate
  54. State of the art paper Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology
  55. Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin
  56. RETRACTED: Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies
  57. Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study
  58. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study
  59. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load
  60. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function
  61. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2‐year study evaluation
  62. Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?
  63. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients
  64. Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients
  65. Leisure-time physical activity and cardiovascular disease mortality
  66. Hypertension: management perspectives
  67. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects
  68. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials
  69. Increasing Diagnosis of Thyroid Papillary Carcinoma Follicular Variant in South-East Anatolian Region: Comparison of Characteristics of Classical Papillary and Follicular Variant Thyroid Cancers
  70. Which statin is the ideal statin for polymedicated patients?
  71. Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients
  72. Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients
  73. Antidiabetic Properties of Berberine: From Cellular Pharmacology to Clinical Effects
  74. The Role of Irbesartan in the Treatment of Patients with Hypertension
  75. Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample
  76. Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women
  77. 25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive women
  78. State of the art paper Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects
  79. State of the art paper Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions
  80. Metabolic Syndrome, Adipokines and Hormonal Factors in Pharmacologically Untreated Adult Elderly Subjects from the Brisighella Heart Study Historical Cohort
  81. Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents Metformin and its clinical use: new insights for an old drug in clinical practice
  82. Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents
  83. Kidney disease and inner ear impairment: a simpler and closer pathogenic analogy?
  84. Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice
  85. Hypertension and diabetes incidence: confounding factors
  86. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial
  87. RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study
  88. Tinnitus in elderly patients and prognosis of mild-to-moderate congestive heart failure: a cross-sectional study with a long-term extension of the clinical follow-up
  89. Effects of n‐3 PUFA on insulin resistance after an oral fat load
  90. From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study
  91. Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients
  92. The relationship between calcium metabolism, insulin-like growth factor-1 and pulse pressure in normotensive, normolipidaemic and non-diabetic patients
  93. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load
  94. Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study
  95. Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension
  96. Hemodynamic Effects of Lactotripeptides from Casein Hydrolysate in Mediterranean Normotensive Subjects and Patients with High-Normal Blood Pressure: A Randomized, Double-Blind, Crossover Clinical Trial
  97. Hemodynamic and neurohumoral profile in patients with different types of hypertension in pregnancy
  98. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients
  99. Comparison between orlistat plus l‐carnitine and orlistat alone on inflammation parameters in obese diabetic patients
  100. Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension
  101. Psychosocial factors and metabolic parameters: Is there any association in elderly people? The Massa Lombarda Project
  102. Relationship between serum zinc levels, thyroid hormones and thyroid volume following successful iodine supplementation
  103. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
  104. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients
  105. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
  106. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients
  107. Red Yeast Rice and Statin-Intolerant Patients
  108. Omega 3 Polyunsaturated Fatty Acids Supplementation and Blood Pressure Levels in Hypertriglyceridemic Patients with Untreated Normal-High Blood Pressure and With or Without Metabolic Syndrome: A Retrospective Study
  109. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects
  110. Weight loss and blood pressure normalization: the relevance of early interventions in hypertension
  111. Candesartan effect on inflammation in hypertension
  112. A Web2.0 Platform in Healthcare Created on the Basis of the Real Perceived Need of the Elderly End User
  113. Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans
  114. Long-term Effect of a Dietary Education Program on Postmenopausal Cardiovascular Risk and Metabolic Syndrome: The Brisighella Heart Study
  115. Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients
  116. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients
  117. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment
  118. Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome
  119. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results
  120. Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin‐treated hypertensive hypercholesterolemic patients
  121. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long‐term Evaluation trial
  122. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study
  123. Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
  124. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
  125. Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years
  126. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects
  127. Effects of Telmisartan and Bisoprolol on Blood Pressure, Peripheral Haemodynamic and Lipid Profile in Statin-Treated Hypertensive Hypercholesterolaemic Patients
  128. Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
  129. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial
  130. Hypertension and hypercholesterolemia: from theory to cardiovascular disease risk prevention. Second edition
  131. Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine
  132. Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives
  133. Effects of Insulin Therapy with Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Patients: Comparison with Multi-daily Insulin Injections Therapy (MDI)
  134. Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
  135. Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
  136. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone
  137. Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin
  138. Changes in LDL Fatty Acid Composition as a Response to Olive Oil Treatment Are Inversely Related to Lipid Oxidative Damage: The EUROLIVE Study
  139. Non-pharmacological control of plasma cholesterol levels
  140. Hypertension and hypercholesterolemia: from theory to cardiovascular disease risk prevention
  141. Global Cardiovascular Disease Risk Management in Italian Patients with Metabolic Syndrome in the Clinical Practice Setting
  142. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome
  143. Sources of variability of plasma HDL-cholesterol levels
  144. Interaction between serum cholesterol levels and the renin–angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure
  145. Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
  146. Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
  147. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial
  148. Activity and potential role of licofelone in the management of osteoarthritis
  149. Blood Pressure Modulating Properties of Omega-3 Polyunsaturated Fatty Acids (PUFA)
  150. Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin
  151. Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naïve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial
  152. Different Effect of Psyllium and Guar Dietary Supplementation on Blood Pressure Control in Hypertensive Overweight Patients: A Six-Month, Randomized Clinical Trial
  153. Metalloproteinase-2 and -9 in Diabetic and Nondiabetic Subjects during Acute Coronary Syndromes
  154. Persistence on Treatment and Blood Pressure Control with Different First-Line Antihypertensive Treatments: A Prospective Evaluation
  155. Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data
  156. Irbesartan: a review of its use alone and in combination with hydrochlorothiazide
  157. Physical activity, exercise and cardiovascular health
  158. Recent evidence of the role of omega-3 polyunsaturated fatty acids on blood pressure control and hypertension-related complications
  159. Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management
  160. Metabolic syndrome prevalence in Italy
  161. Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus
  162. Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Control...
  163. Effect of Doxazosin on C-Reactive Protein Plasma Levels and on Nitric Oxide in Patients With Hypertension
  164. Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
  165. Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.
  166. Matrix Metalloproteinase-2, -9, and Tissue Inhibitor of Metalloproteinase-1 in Patients with Hypertension
  167. Synergistic Effect of Doxazosin and Acarbose in Improving Metabolic Control in Patients with Impaired Glucose Tolerance
  168. Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy
  169. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot study
  170. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: A 12-month, double-blind, randomized clinical trial
  171. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome
  172. Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension
  173. Antithrombotic Effects of Rosiglitazone-Metformin versus Glimepiride-Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome
  174. Adverse reactions related to drugs for headache treatment: clinical impact
  175. Complementary and Alternative Medicine for Hypertension
  176. Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly
  177. Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride
  178. Effect of oral chronic isoflavones supplementation on male rat sexual performances and sexual hormone plasma levels
  179. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, do...
  180. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept
  181. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial
  182. Effects of a new low dose soy protein/?-sitosterol association on plasma lipid levels and oxidation
  183. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus
  184. The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus
  185. Clinical considerations preliminary to application of the Italian Society for the Study of Headache's guidelines regarding migraine prophylactic treatment
  186. It Is Necessary to Prevent a Cerebrovascular ‘Pandemia’
  187. Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a ‘Pandemia’
  188. Asymptomatic Massive Hypertriglyceridemia in an Octogenarian
  189. Effects of a New Soy/β-Sitosterol Supplement on Plasma Lipids in Moderately Hypercholesterolemic Subjects
  190. Letter to Editor: Hypercholesterolemia underdiagnosis and undertreatment in psychiatric patients in Italy
  191. Application of a New Processing Method to Post‐LDL‐apheresis Data
  192. Triptans: the experience of a clinical pharmacologist in clinical practice